G1 THERAPEUTICS INC's ticker is GTHX and the CUSIP is 3621LQ109. A total of 115 filers reported holding G1 THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 1.16 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $1,688 | +84300.0% | 678 | 0.0% | 0.00% | – |
Q1 2023 | $2 | -50.0% | 678 | 0.0% | 0.00% | – |
Q4 2022 | $4 | -99.9% | 678 | 0.0% | 0.00% | – |
Q3 2022 | $7,000 | +133.3% | 678 | 0.0% | 0.00% | – |
Q2 2022 | $3,000 | -81.2% | 678 | -67.4% | 0.00% | – |
Q1 2022 | $16,000 | +128.6% | 2,078 | +206.5% | 0.00% | – |
Q4 2021 | $7,000 | -61.1% | 678 | -50.8% | 0.00% | – |
Q3 2021 | $18,000 | -40.0% | 1,378 | 0.0% | 0.00% | – |
Q2 2021 | $30,000 | -9.1% | 1,378 | 0.0% | 0.00% | – |
Q1 2021 | $33,000 | +32.0% | 1,378 | 0.0% | 0.00% | – |
Q4 2020 | $25,000 | +400.0% | 1,378 | +222.0% | 0.00% | – |
Q3 2020 | $5,000 | -50.0% | 428 | 0.0% | 0.00% | – |
Q2 2020 | $10,000 | +100.0% | 428 | 0.0% | 0.00% | – |
Q1 2020 | $5,000 | -28.6% | 428 | +59.7% | 0.00% | – |
Q4 2019 | $7,000 | -98.8% | 268 | -98.9% | 0.00% | -100.0% |
Q3 2019 | $576,000 | +3740.0% | 25,268 | +4953.6% | 0.01% | – |
Q2 2019 | $15,000 | +650.0% | 500 | +233.3% | 0.00% | – |
Q1 2019 | $2,000 | -33.3% | 150 | 0.0% | 0.00% | – |
Q4 2018 | $3,000 | -62.5% | 150 | 0.0% | 0.00% | – |
Q3 2018 | $8,000 | – | 150 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
MPM BioImpact LLC | 1,423,794 | $34,541,000 | 9.18% |
Burrage Capital Management LLC | 373,876 | $9,070,000 | 6.35% |
Birchview Capital, LP | 40,000 | $970,000 | 0.59% |
361 CAPITAL LLC | 47,325 | $1,148,000 | 0.54% |
Rhenman & Partners Asset Management AB | 190,000 | $4,609,000 | 0.50% |
CHI Advisors LLC | 44,000 | $1,067,000 | 0.42% |
Bellevue Group AG | 721,925 | $17,514,000 | 0.25% |
Candriam S.C.A. | 870,423 | $21,117,000 | 0.22% |
Virtus ETF Advisers LLC | 18,991 | $461,000 | 0.22% |
HHLR ADVISORS, LTD. | 949,431 | $23,033,000 | 0.21% |